Hemera Pharma

Hemera is an Italian biotechnology company dedicated to developing innovative regenerative medicine therapies for neurological disorders, with a primary focus on spinal cord injury (SCI). A spin-off from the University of Verona and the University of Milan, the company is developing its lead candidate, HMR-001, an autologous cell therapy based on a specific population of pro-regenerative macrophages. This approach aims to modulate the inflammatory environment at the site of injury and promote tissue repair and functional recovery. Hemera's technology seeks to address the significant unmet medical need in both acute and chronic spinal cord injury patients.